Mission Wealth Management LP Buys 9,086 Shares of Novartis AG $NVS

Mission Wealth Management LP increased its stake in shares of Novartis AG (NYSE:NVS) by 85.7% during the second quarter, HoldingsChannel.com reports. The fund owned 19,690 shares of the company’s stock after purchasing an additional 9,086 shares during the period. Mission Wealth Management LP’s holdings in Novartis were worth $3,086,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. J.W. Cole Advisors Inc. lifted its position in Novartis by 0.6% during the 4th quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock worth $1,348,000 after acquiring an additional 64 shares during the last quarter. Roundview Capital LLC grew its position in shares of Novartis by 2.5% in the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock valued at $374,000 after purchasing an additional 66 shares during the last quarter. IMA Advisory Services Inc. increased its stake in shares of Novartis by 10.9% in the fourth quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after purchasing an additional 70 shares during the period. Moody National Bank Trust Division boosted its holdings in Novartis by 4.2% in the 2nd quarter. Moody National Bank Trust Division now owns 1,802 shares of the company’s stock valued at $282,000 after purchasing an additional 72 shares during the period. Finally, Abundance Wealth Counselors grew its position in Novartis by 0.4% in the 4th quarter. Abundance Wealth Counselors now owns 16,927 shares of the company’s stock worth $2,334,000 after purchasing an additional 73 shares during the last quarter. 13.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on NVS shares. Citigroup reaffirmed a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $141.20.

Novartis Trading Down 1.5%

NVS opened at $152.35 on Thursday. Novartis AG has a 1-year low of $119.97 and a 1-year high of $170.46. The stock has a market capitalization of $290.71 billion, a PE ratio of 22.98, a PEG ratio of 2.65 and a beta of 0.45. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The firm has a 50-day moving average price of $153.61 and a two-hundred day moving average price of $153.38.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $14.95 billion for the quarter. As a group, equities analysts anticipate that Novartis AG will post 8.85 earnings per share for the current fiscal year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.